Anti-myeloma activity and molecular logic operation by Natural Killer cells in microfluidic droplets.

ABSTRACT: Immune-targeted therapies that activate effector lymphocytes such as Natural Killer (NK) cells are currently being investigated for the treatment of Multiple myeloma (MM), the second most common form of hematological cancer. However, individual NK cells are highly heterogeneous in their cytolytic potential, making it difficult to detect, quantify and correlate the outcome of dynamic effector-target cell interactions at single cell resolution. Here, we present a microfluidic bioassay platform capable of activity-based screening of cellular and molecular immunotherapies. We identified distinct functional signatures associated with NK-MM cell interaction. The addition of immunomodulatory drug lenalidomide altered responses of NK-susceptible MM cells but not that of NK-tolerant MM cells. Antit

SUBMITTER: Sarkar S 

PROVIDER: S-EPMC6752214 | biostudies-literature | 2019 Mar

REPOSITORIES: biostudies-literature